PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...
– 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing – – PGN-EDODM1 was generally well-tolerated at 15 mg/kg, ...
– Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback